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Abstract
Aims The comparative efficacy of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy on Type 2 diabetes remission
and the role of weight loss are unclear. The DiaRem diabetes remission prediction score uses HbA1c, age and diabetes
medications but not diabetes duration. The aim of this study was to compare the DiaRem with the DiaBetter score that
includes diabetes duration, upon combined (complete plus partial) 2-year post-surgery diabetes remission in people
following RYGB and sleeve gastrectomy, and to investigate the relationship between weight loss and diabetes remission.
Methods A retrospective single-centre cohort study of obese people with diabetes who underwent RYGB (107) or
sleeve gastrectomy (103) and a validation cohort study (173) were undertaken. Diabetes remission, % weight loss,
DiaRem, DiaBetter scores and areas under receiving operator characteristic (ROC) curves were calculated. The
relationship between % weight loss and diabetes remission was investigated using logistic regression.
Results The proportion of people achieving diabetes remission was highest for those with the lowest DiaBetter and
DiaRem scores. Areas under the ROC curves were comparable [DiaBetter: 0.867 (95%CI: 0.817–0.916); DiaRem: 0.865
(95%CI: 0.814–0.915), P=0.856]. Two-year % weight loss was higher post RYGB [26.6 (95%CI: 24.8–28.4)] vs post-
sleeve gastrectomy [20.6 (95%CI: 18.3–22.8), P<0.001]. RYGB had 151% higher odds of diabetes remission [OR 2.51
(95%CI: 1.12–5.60), P=0.025]. This association became non-significant when adjusted for % weight loss.
Conclusion DiaBetter and DiaRem scores predict diabetes remission following both procedures. Two-year % weight
loss plays a key role in determining diabetes remission.
Diabet. Med. 35, 360–367 (2018)
Introduction
Bariatric surgery is the most effective weight loss treatment
for people with a BMI of 40 kg/m2 and of 35 kg/m2 or more
with an obesity-associated co-morbid condition [1]. Bari-
atric surgery leads to marked, sustained weight loss with
amelioration of obesity-related diseases, prevention or delay
of incident Type 2 diabetes and cardiovascular disease, and
reduced mortality [2]. Bariatric surgery is particularly bene-
ficial for people with Type 2 diabetes; up to 60% are able to
maintain normoglycaemia without hypoglycaemic therapy
(remission) at 2 years post surgery [2]. Importantly, longitu-
dinal case-matched studies show that bariatric surgery
reduces the incidence of microvascular complications even
in people who subsequently experience Type 2 diabetes
relapse [3].
Roux-en-Y gastric bypass (RYGB), which involves creating
a small stomach pouch through which ingested nutrients
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empty rapidly into the mid-jejunum, bypassing the duodenum
and proximal jejunum, and sleeve gastrectomy, which involves
removing ~ 70% of the stomach fundus, are the two most
commonly performed bariatric procedures [1]. Postoperative
weight loss is highly variable [4]. RYGB and sleeve gastrec-
tomy differentially impact upon nutrient-stimulated circulat-
ing levels of several gut hormones known to influence insulin
secretion and glucose control [5]. However, it remains unclear
whether RYGB or sleeve gastrectomy benefit people with
Type 2 diabetes equally [6,7].
Randomized clinical trials have shown that bariatric
surgery leads to a superior glycaemic control compared with
medical therapy, with a greater proportion of people
experiencing Type 2 diabetes remission, lower HbA1c levels
and a decrease in hypoglycaemic medications [2,7,8]. Con-
sequently, bariatric surgery is now recognized as a treatment
option for people with Type 2 diabetes with a BMI of 35 kg/
m2 and above [9]. Furthermore, the new guidelines from the
Second Diabetes Surgery Summit (DSS-II), endorsed by 45
international professional organizations, urge that bariatric
surgery is considered in subjects with a BMI of 30–34.9 kg/
m2 who fail to respond to conventional treatment [9].
However, access to bariatric surgery is limited and postop-
erative weight loss and glycaemic improvement are variable
[4]. Longer Type 2 diabetes duration, low preoperative C-
peptide levels, insulin usage and poor postoperative weight
loss are associated with reduced likelihood of Type 2
diabetes remission [3]. Predictive outcome scores for Type
2 diabetes remission encapsulating these factors have been
developed and may be useful in prioritizing those most likely
to benefit. However, C-peptide, and fasted insulin and
glucose are not routinely measured in the real-world setting
[10]. The DiaRem score, developed in people who had
undergone RYGB, is based upon age, HbA1c and hypogly-
caemic medications and associates with Type 2 diabetes
remission [11]. However, a recent study reported that the
DiaRem score, which does not include Type 2 diabetes
duration, has limited negative predictive power (for a low
chance of remission) in an ethnically diverse British cohort at
1 year after RYGB [12]. In addition, there are no studies
examining the performance of the DiaRem score at predict-
ing Type 2 diabetes remission following sleeve gastrectomy.
We undertook a retrospective cohort study and a separate
validation study in people with 2-year outcome data follow-
ing RYGB or sleeve gastrectomy to compare the predictive
value of the DiaRem score with a novel score based upon
Type 2 diabetes duration, HbA1c and hypoglycaemic med-
ication usage, the DiaBetter score upon Type 2 diabetes
remission. Next, we examined the effect of procedure type,
RYGB or sleeve gastrectomy, upon 2-year post-surgery
weight loss and glycaemic outcomes. Finally, we examined
the relationship between Type 2 diabetes remission and
weight loss.
Methods
A retrospective cohort study was undertaken at University
College London Hospitals (UCLH) National Health Service
(NHS) Foundation Trust, London, UK. Demographic,
anthropometric and clinical data were collected by review
of prospectively maintained clinical records within a single
bariatric surgery unit at UCLH Bariatric Centre for Weight
Management and Metabolic Surgery. People aged 18 years
or over, with a BMI ≥ 35.0 kg/m2 and Type 2 diabetes, who
underwent either primary RYGB or sleeve gastrectomy
procedures with complete 2-year follow-up data were
included. People undergoing bariatric surgery were evaluated
pre- and postoperatively by a multidisciplinary team con-
sisting of physicians, surgeons, clinical nurse specialists,
psychologists, dieticians and anaesthetists. Procedure selec-
tion was based on informed patient preference after stan-
dardized counselling including the provision of written and
verbal information detailing the risks and benefits of
each procedure and the multidisciplinary team decision.
Informed written consent was obtained prior to surgery. Post
surgery, people were advised to follow a liquid diet for
2 weeks, followed by softer foods for a further 2 weeks,
before resuming a solid diet thereafter. The postoperative
follow-up schedule comprised of appointments at 4–
6 weeks, then 3-monthly during the first year and 6–12-
monthly thereafter. RYGB and sleeve gastrectomy were
undertaken as described previously [13]. Age was calculated
as the difference between the date of birth and date of
surgery. Baseline BMI was calculated from the weight
measured in kg, divided by the square of height measured
in metres on the day of surgery. Postoperative weight loss
What’s new?
• Roux-en-Y gastric bypass (RYGB) and sleeve gastrec-
tomy can lead to Type 2 diabetes remission in people
with obesity and Type 2 diabetes. The impact of post-
surgery weight loss and surgical procedure type upon
Type 2 diabetes remission rates are unclear.
• The DiaRem score predicts post-RYGB Type 2 diabetes
remission but does not include Type 2 diabetes dura-
tion, which negatively associates with Type 2 diabetes
remission rates.
• We show that the novel DiaBetter Score, which includes
Type 2 diabetes duration, predicts Type 2 diabetes
remission at 2 years following RYBG and sleeve
gastrectomy with comparable predictive power to
DiaRem.
• Importantly, we show that percentage weight loss
rather than procedure type determines Type 2 diabetes
remission 2 years postoperatively.
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was determined relative to the weight on the day of surgery.
Percentage weight loss was chosen as the outcome measure
for weight change, as it is less influenced by baseline BMI
than per cent excess weight loss.
Complete or partial Type 2 diabetes remission were
defined using the DSS-II Consensus group criteria [HbA1c
< 42 mmol/mol (6.0%) or < 48 mmol/mol (6.5%) respec-
tively for 12 months or longer without any Type 2 diabetes
medication] [9]. Type 2 diabetes duration was defined as the
difference between the date of Type 2 diabetes diagnosis and
date of surgery. At 2 years post surgery, the number of
people with combined Type 2 diabetes remission (total and
partial remission) and no remission were calculated. The
DiaBetter score was designed according to the TRIPOD
guidelines [14], and based upon HbA1c, Type 2 diabetes
duration and anti-diabetic medications (Table 1) with a
score ranging between 0 and 3 for each variable. The scoring
categories for HbA1c and Type 2 diabetes duration were
obtained by dividing our population in quartiles.
The DiaBetter score (range 0–9; Table 1) and DiaRem
score (range 0–22; Table 2) were calculated for each person.
People were then stratified into one of five score groups for
both DiaBetter and DiaRem. The distribution of the HbA1c
level, Type 2 diabetes duration and anti-diabetic medications
in each DiaBetter score group and the odds of Type 2
diabetes remission by these individual predictor variables are
presented in Tables S1 and S2. The percentage of people with
Type 2 diabetes remission within each group was calculated.
Baseline population characteristics and pre- and post-surgery
determinants of Type 2 diabetes remission by procedure type
were examined using chi-square tests and t-tests. Nonpara-
metric receiver operating characteristic (ROC) curves, a
graph of the sensitivity vs 1-specificity of the diagnostic test
[15] were used to compare the diagnostic value of the
DiaBetter and DiaRem using the continuous scores. Logistic
regression was utilized to examine odds of Type 2 diabetes
remission by procedure type adjusted for baseline Type 2
diabetes score (basic model). These analyses were further
adjusted for age, gender and BMI and per cent weight loss at
2 years post surgery, measured on a continuous scale. Finally,
odds of remission were tested using per cent weight loss
measured on a continuous scale, categorized into 5% weight
loss groups and in quintiles as exposure. Using the likelihood
ratio test, we evaluated the assumption of linearity and found
that the odds of Type 2 diabetes remission increased linearly
with each 5% weight loss category and thus a pooled odds
ratio is presented. The basic model controlling for the
DiaBetter and DiaRem was further adjusted for age (in the
DiaBetter model only), sex and baseline BMI to rule out
potential confounders, as these variables have been associ-
ated with both Type 2 diabetes remission and per cent weight
loss at 2 years post surgery. All analyses were performed in
Stata 13 (Stata Corp., College Station, TX, USA). A separate
validation analysis was undertaken in an independent cohort
of 173 people, 114 RYGB and 59 sleeve gastrectomy, from
two centres: UCLH (new cohort, 113) and Centro Hospitalar
de Entre o Douro e Vouga, Santa Maria da Feira, Portugal
(60) to validate the DiaBetter score.
Table 1 DiaBetter Score. A score ranging between 0 and 3 was allocated for HbA1c, Type 2 diabetes duration and antidiabetic medications.
Different scores for HbA1c and Type 2 diabetes duration were obtained dividing our population into quartiles. The medication score was obtained
according to the usual medical history of people with Type 2 diabetes and of their pancreatic function (diet, metformin, other medications and finally
insulin). By combining these three scores an estimate of Type 2 diabetes severity was obtained with a baseline total score ranging from 0 to 9 points.
People were stratified in five groups based on score
Score 0 Score 1 Score 2 Score 3
HbA1c mmol/mol (%) ≤ 48 (≤ 6.5) 49 (6.6) - 55 (7.2) 56 (7.3) - 68 (8.4) ≥ 69 (8.5)
Duration of Type 2 Diabetes (years) ≤ 2.0 2.1 – 5.0 5.1 -10.0 ≥ 10.1
Anti-Diabetes Medication None Metformin Other non-insulin drug Insulin alone or in combination
Total Score (0-9) 0 or 1 2 or 3 4 or 5 6 or 7 8 or 9
Group 1 2 3 4 5
Table 2 DiaRem Score. This score was obtained using four preoperative parameters: (1) HbA1c, (2) age, (3) use of oral hypoglycaemic agents and (4)
use of insulin. The total score ranges between 0 and 22 and is obtained adding the score for every single parameter. People were stratified into five
score groups as proposed by Still et al. [11]
HbA1c mmol/mol (%) < 48 (< 6.5) ≥ 48 (6.5) and ≤ 52 (6.9) ≥ 53 (7.0) and ≤ 74 (8.9) ≥ 75 (9.0)
Score 0-6 Score 0 Score 2 Score 4 Score 6
Age (years) < 40 40-49 50-59 ≥ 60
Score 0-3 Score 0 Score 1 Score 2 Score 3
Anti-Diabetes Medication None Metformin Other non-insulin drug Insulin
Score 0-13 Score 0 Score 0 Score 3 Score 10
Total Score (0-22) 0-2 3-7 8-12 13-17 18-22
Group 1 2 3 4 5
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Results
Some 346 adults with Type 2 diabetes who underwent either
primary RYGB or primary sleeve gastrectomy between
January 2008 and December 2015 were identified. One
hundred and thirty-six were excluded due to incomplete 2-
year follow-up data (Fig. S1). Comparison of people with
complete vs incomplete data revealed no statistical differ-
ences in post-surgery weight loss or pre-surgery data except
that people with incomplete data were younger (Table S3). In
total, 107 people who underwent RYGB and 103 who
underwent sleeve gastrectomy were included in the retro-
spective primary cohort study. There were no differences
between the RYGB and sleeve gastrectomy groups in terms
of gender, age, ethnicity, mean HbA1c values, Type 2
diabetes duration and hypoglycaemic medications at base-
line. There were significant group differences in baseline
weight and BMI (higher in the sleeve gastrectomy group),
and in insulin usage (higher proportion in the RYGB group).
People who underwent RYGB showed higher DiaRem and
DiaBetter scores at baseline (Table 3).
At 2 years post-surgery, combined Type 2 diabetes
remission was achieved in 144 (68.6%) of 210 people. The
proportion of people achieving Type 2 diabetes remission
was highest for those with the lowest DiaBetter and DiaRem
scores and lowest in those with the highest scores, with a
significant difference across the groups for both scores
(Table 4). The diagnostic value of DiaRem and DiaBetter
for Type 2 diabetes combined remission using the values of
specificity and sensitivity were similar (Table S4). The area
under the ROC curve for the DiaBetter and DiaRem scores
were similar [DiaBetter: 0.867 (95% CI: 0.817–0.916) and
DiaRem: 0.865 (95% CI: 0.814–0.915), P = 0.856, Fig. 1).
The validation cohort baseline characteristics, DiaRem and
DiaBetter scores and 2-year post-surgery per cent weight loss
and percentage of combined remission are presented in
Table S5. The proportion of people achieving Type 2
diabetes remission was significantly higher for those with
the lowest DiaBetter and DiaRem scores compared with
those with the highest scores (Table S5). Area under the ROC
curve analyses were similar to the primary cohort (Fig. 2).
Mean per cent weight loss was higher in the RYGB group
than the sleeve gastrectomy group [26.6 (95% CI: 24.8–28.4)
vs 20.6 (95% CI: 18.3–22.8), P < 0.001]. Combining the
RYGB and sleeve gastrectomy groups showed 2-year post-
surgery remission was associated with younger age, female
gender, higher BMI, lower HbA1c and lower DiaRem and
DiaBetter scores at baseline. When stratifying by procedure
type some of these associations were attenuated or became
statistically insignificant due to low numbers (Table 4).
At 2 years post surgery, the sleeve gastrectomy group had a
higher HbA1c level, 0.37% (95% CI: 0.09–0.65, P = 0.009)
than the RYGB group after controlling for baseline DiaBetter
score. However, after adjusting for 2-year per cent weight
loss, the association with surgery type was no longer
statistically significant (P = 0.199). We obtained the same
results when controlling for the DiaRem score [0.43% higher
HbA1c in the sleeve gastrectomy group (95% CI: 0.14–0.75,
P = 0.003), not significant after adjusting for per cent weight
loss (P = 0.103)]. When comparing people with Type 2
diabetes with combined remission vs no remission and
adjusting for DiaBetter score we found that people who
underwent RYGB had 151% higher odds of Type 2 diabetes
combined remission vs no remission compared to sleeve
gastrectomy [odds ratio (OR) 2.51, 95% CI: 1.12–5.60, P =
0.025] (Table 5). When considering complete remission
only, the odds of Type 2 diabetes combined remission where
193% higher (OR 2.93, 95% CI: 1.26–6.81, P = 0.012).
However, when per cent weight loss was adjusted for, this
association became non-significant both for combined
Table 3 Comparison between baseline characteristics for people with Type 2 diabetes (137 females; 73 males) undergoing Roux-en-Y gastric bypass




(n = 103) P-value
Age (years); mean (SD) 51.6 (8.0) 49.7 (8.8) NS
Ethnicity (Caucasian); n (%) 83 (78) 76 (74) NS
BMI (kg/m2); mean (SD) 43.1 (6.3) 48.2 (7.8) <0.001
Type 2 diabetes duration (years); mean (SD) 5.6 (5.1) 4.7 (5.4) NS
HbA1c; % (SD) 62, 7.8 (1.5) 57, 7.3 (1.4) NS
Prescribed Type 2 diabetes medication; n (%) 85 (52) 77 (48) NS
Prescribed insulin; n (%) 26 (70) 11 (30) < 0.05
Prescribed metformin; n (%) 80 (75) 70 (68) NS
Prescribed sulphonylurea; n (%) 29 (27) 24 (23) NS
Prescribed thiazolidinedione; n (%) 13 (12) 14 (14) NS
Prescribed DPP-4 inhibitor; n (%) 4 (4) 1 (1) NS
Prescribed SGLT2 inhibitor; n (%) 0 (0) 0 (0) NS
Prescribed GLP-1 receptor agonist; n (%) 14 (13) 11 (11) NS
DiaRem total score (SD) 8.3 (5.2) 6.0 (4.4) < 0.001
DiaBetter total score (SD) 4.4 (2.7) 3.4 (2.4) < 0.05
RYGB, Roux-en-Y gastric bypass; DPP-4, dipeptidyl peptidase-4; SGLT2, sodium–glucose co-transporter-2; GLP-1, glucagon-like peptide-1;
NS, non-significant
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remission (OR 1.69, 95% CI: 0.72–3.97, P > 0.05, Table 5)
and complete remission (OR 1.74, 95% CI: 0.70–4.30, P >
0.05). When adjusting for DiaRem score we found that the








































































































































































































































































































































































































































































































































































































































































































FIGURE 1 Comparison of the diagnostic value of DiaBetter and
DiaRem (continuous scores) in the study population (n = 210) using the
nonparametric receiver operating characteristic (ROC) plot. This test is
used to classify the accuracy of a prediction model and the closer the
area under the curve to a value of 1, the more accurate the model.
Sensitivity is shown on the y-axis and specificity on the x-axis.
DiaBetter prediction score is shown by the filled circles and solid line,
and DiaRem by the open squares and a dotted line. Area under the
DiaBetter ROC curve and DiaRem ROC curve with 95% confidence
intervals and P-value for the test of equality of ROC areas is shown.
The diagonal line is the line of no discrimination, it divides the ROC
space into two, the points above the diagonal represent good
classification results (better than random), points below the line
represent poor results (worse than random).
FIGURE 2 Comparison of the diagnostic value of DiaBetter and
DiaRem (continuous scores) in the validation population (n = 173)
using the nonparametric receiver operating characteristic (ROC) plot.
DiaBetter prediction score is shown by filled circles and a solid line, and
DiaRem by open squares and a dotted line. Area under the DiaBetter
ROC curve and DiaRem ROC curve with 95% confidence intervals
and p value for the test of equality of ROC areas is shown. The
diagonal line is the line of no discrimination, it divides the ROC space
into two, the points above the diagonal represent good classification
results (better than random), points below the line represent poor
results (worse than random).
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(OR 2.75, 95% CI: 1.25–6.05, P = 0.012, Table 5). Also in
this case, when per cent weight loss was adjusted for, this
association became non-significant (OR 1.82, 95% CI: 0.79–
4.22, P > 0.05, Table 5).
Next, we evaluated the odds of combined remission by per
cent weight loss categorized in quintiles, 5% weight loss
groups and as a continuous variable (Tables S6 and S7).
When testing the odds of Type 2 diabetes remission by
quintiles of per cent weight loss and adjusting for DiaBetter
score, we found that those in either the third, fourth or fifth
highest quintile (per cent weight loss > 21.15) had signifi-
cantly higher odds of Type 2 diabetes combined remission
than subjects in the first quintile (per cent weight loss <
16.51) (Table S8). When considering complete remission
only, we found that those in the second, third, fourth and
fifth quintiles (per cent weight loss > 16.51%) had signif-
icantly higher odds of remission than people in the first
quintile (per cent weight loss < 16.51). When testing the odds
of Type 2 diabetes remission adjusting for DiaRem score we
found similar results (Table S8); when adjusting for DiaBet-
ter score, for every 1% weight loss, the odds of Type 2
diabetes combined remission increased by 7% (OR 1.07,
95% CI: 1.03–1.12, P < 0.001). This association remained
after adjustments for age, gender, BMI and surgery type.
Furthermore, the odds of Type 2 diabetes combined remis-
sion increased by 54% with each 5% of weight lost (OR
1.54, 95% CI: 1.21–1.96, P < 0.001), age, gender, BMI and
surgery type had no effect on these associations (Table S9).
Adjusting for DiaRem, for every 1% weight loss, odds of
Type 2 diabetes combined remission increased by 8% (OR
1.08, 95% CI: 1.04–1.13, P < 0.001) and with every unit
increase in the grouping of 5% weight loss by 63% (OR
1.63, 95% CI: 1.29–2.07, P < 0.001) with no effect on these
associations from gender, BMI and surgery type (Table S9).
Discussion
Bariatric surgery is established as a treatment option for
people with obesity and Type 2 diabetes, with many people
experiencing Type 2 diabetes remission postoperatively [2].
However, access to bariatric surgery is limited and surgery
carries a mortality risk, albeit small, together with the risk of
post-surgery complications and the need for life-long nutri-
tional supplementation and follow-up [1]. Furthermore,
weight loss and glycaemic improvements following RYGB
and sleeve gastrectomy are highly variable [2]. Adopting a
personalized approached to bariatric surgery by identifying
which people with Type 2 diabetes will benefit most and
maximizing their postoperative care to reduce their future
risk of Type 2 diabetes-related complications will increase
the benefit to risk ratio for people with Type 2 diabetes. The
DiaRem score does not include Type 2 diabetes duration,
which associates with the probability of Type 2 diabetes
remission and is a key determinant of access to surgery in the
UK [16]. The number of people developing Type 2 diabetes
at a younger age is increasing, particularly within those of
Asian origin [17,18]. Thus, we developed the DiaBetter score
to include Type 2 diabetes duration. Sleeve gastrectomy is
now the most common surgical procedure undertaken
globally, but there are no studies reporting the predictive
value of the DiaRem score in people with Type 2 diabetes
following sleeve gastrectomy. Hence, we undertook a retro-
spective study to compare the ability of the DiaRem and
DiaBetter scores to predict Type 2 diabetes remission at 2
years following RYGB or sleeve gastrectomy. The DiaBetter
and DiaRem scores had comparable predictive value in both
RYGB and sleeve gastrectomy cohorts, with people in the
lowest score group exhibiting the highest rates of Type 2
diabetes remission and those in the highest score the lowest
Type 2 diabetes remission rates. Our primary cohort was
predominantly Caucasian and had an average age of
50.6  8.4 years, future studies are needed to compare the
DiaBetter and DiaRem scores in younger cohorts and in
mixed ethnic groups.
Currently, it is unclear whether people with Type 2
diabetes should be offered RYGB or sleeve gastrectomy. In
agreement with a meta-analysis including 16 studies of
> 9000 obese people undergoing either RYGB or sleeve
gastrectomy [19], we found that those with Type 2 diabetes
who underwent RYGB obtained greater weight loss





Basic model adjusting for DiaBetter score 2.51 1.03 1.12–5.59 0.025
+ age (years) 2.68 1.11 1.19–6.06 0.018
+ gender (women vs men) 2.41 1.00 1.07–5.44 0.034
+ BMI (kg/m2) 2.78 1.19 1.20–6.44 0.017
+ % weight loss at 2 years’ post surgery 1.69 0.74 0.72–3.97 0.232
Basic model* adjusting for DiaRem score 2.75 1.10 1.25–6.05 0.012
+ gender (women vs men) 2.68 1.09 1.20–5.97 0.016
+ BMI (kg/m2) 3.09 1.30 1.35–7.05 0.007
+ % weight loss at 2 years’ post surgery 1.82 0.77 0.79–4.22 0.157
*Age is included in DiaRem.
ª 2017 The Authors
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 365
Research article DIABETICMedicine
outcomes than those who underwent sleeve gastrectomy.
Although several on-going randomized controlled trials
comparing RYGB to sleeve gastrectomy have reported no
difference in weight loss between these two procedures, these
studies have relatively small numbers of people with Type 2
diabetes and are not powered to detect differences between
procedures in those with Type 2 diabetes [6,7,20].
Importantly, our findings show that at 2 years, per cent
weight loss rather than procedure type, is the key determinant
of Type 2 diabetes remission. Several other studies have
reported the importance of weight loss as a determinant of
improved glycaemic control following bariatric surgery
[21,22]. For example, the 10-year post-surgery data from
the Swedish Obese Study also reported that the degree of
weight loss was a more important determinant of reduced
fasting insulin and glucose than the procedure choice [23].
Furthermore, in the STAMPEDE randomized trial comparing
medical intervention alone or with RYGB or sleeve gastrec-
tomy, change in BMI was the only independent predictor of
achieving the primary outcome measure of the study [HbA1c
< 42 mmol/mol (6.0%) with or without medical therapy] [7].
Here, we demonstrated that for every 1% weight loss, the
odds of Type 2 diabetes remission increased by 7%, and for
each 5% weight loss by 54%. This observation supports the
need to maximize weight loss outcomes after bariatric
surgery. In a recent study, we observed in a population with
poor weight loss post surgery how an intervention pro-
gramme combining exercise training with nutritional–be-
havioural counselling contributed to a greater weight loss at
12 months compared with a matched control group [24].
The strengths of this study include: using the updated and
more rigorous consensus definition of Type 2 diabetes
remission; examining 2-year post-surgery weight loss and
Type 2 diabetes outcomes in people with Type 2 diabetes
following RYGB and sleeve gastrectomy with > 100 people
per group; use of a separate validation group; and correcting
for baseline confounding factors, which enabled us to
examine the impact of per cent weight loss per se. Our
retrospective cohort study has several limitations. First,
people were not randomized to RYGB or sleeve gastrectomy,
leading to a potential selection bias and differences in
baseline risk for Type 2 diabetes remission. Second, the date
of Type 2 diabetes onset may be inaccurate due to a long
period of unrecognized hyperglycaemia preceding clinical
diagnosis, with the effect of underestimating Type 2 diabetes
duration. Third, we examined 2-year post-surgery outcomes,
which have been shown to impact subsequent microvascular
complication rates. However, longer term studies are
required. Our sample size was limited and data collection
retrospective. A large multicentre randomized controlled
prospective trial with prospective evaluation of the DiaRem
and DiaBetter scores comparing per cent weight loss and
Type 2 diabetes remission in people with Type 2 diabetes
undergoing RYGB or sleeve gastrectomy encompassing a
wider age range and different ethnicities is now warranted.
In conclusion, our single-centre retrospective study com-
paring the impact of sleeve gastrectomy and RYGB upon
combined remission of Type 2 diabetes at 2 years post surgery
found that the DiaBetter and DiaRem scores had comparable
predictive value in our population. Per cent weight loss rather
than procedure type was associated with combined remission.
Our findings suggest that per cent weight loss plays a major
role in determining glycaemic improvements after metabolic
bariatric procedures and provides a strong argument for
management strategies focused upon optimizing weight loss
following bariatric surgery.
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